Abstract 2064P
Background
Hospitalisation is an inevitable step in the evolution of many patients with cancer, principally in advanced tumors. This study aims to describe the admissions to a medical oncology inpatient service of our University Hospital between November 2022 and April 2023.
Methods
We conducted a retrospective cross-sectional study of patients admitted to the Medical Oncology Service of Infanta Sofía University Hospital (Madrid) along six months. Database was collected from the electronic health records. The following variables were analyzed: age, sex, type of tumor, stages, origin of the admission, period of hospital stay, diagnoses, assessment by another specialities, type of discharge and readmissions.
Results
In the chosen period, 310 hospitalisations related to 223 patients were studied, because some of them were readmitted in these six months. The average age was 71.49 years, 42.9% women and 57.1% men. The average hospital stay was 10.18 days. Near 77% of the patients had advanced disease. In order of frequency, patients with lung (28.06%), colorectal (15.8%) and genitourinary (11.94%) cancer represented the most of inpatients. Mainly the patients were admitted from the Emergency Department of our Hospital (56.45%). The most prevalent reason for hospitalisation was secondary symptoms of disease progression. Infections were the cause of admission in 24.52% of the cases and 27.42% of them were from respiratory system. Other causes to take into account were the toxicity to the treatment (5.8%). As part of the multidisciplinary approach, during their hospitalisation, 5.26% inpatients required surgical assessment. Interventional radiologists treated 1.29% patients and endocrinologists providing nutritional support in 10.65% of cases. Furthermore, less than 2% of our patients were admitted to the Intensive Care Unit. Palliative Care Unit assessed 37.74% of the inpatients, which 19.35% were being previously followed-up by them. Unfortunately 15.8% of the admitted patients died. We also observed 26.45% had to be admitted again.
Conclusions
It is important to identify the reasons why patients with cancer are admitted to the Hospital because it could help to identify areas for improvement in the quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06